<DOC>
	<DOCNO>NCT02296996</DOCNO>
	<brief_summary>Patients BRAF V600 mutant advance melanoma benefit treatment BRAF-inhibitor ( e.g . dabrafenib , vemurafenib ) combination BRAF- MEK-inhibitor ( e.g . dabrafenib trametinib ) . Following initial tumor regression , progression diagnose majority patient treat BRAF-inhibitor mono-therapy within first 12-months therapy . Various molecular mechanism underlie development resistance treatment BRAF-inhibitor report . These mechanism include secondary mutation BRAF-gene therefore resistance BRAF-inhibition could potentially reversible selective pressure BRAF-inhibition withheld sufficient period time melanoma progression . This clinical trial protocol address potential renew anti-tumor activity combine BRAF- MEK inhibition combination dabrafenib trametinib patient unresectable AJCC stage III - IV BRAF V600 mutant melanoma document progression disease least 12 week follow last day dose BRAFinhibitor contain treatment regimen .</brief_summary>
	<brief_title>Dabrafenib Trametinib BRAF-inhibitor Pretreated Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>1 . 18 year age sign write informed consent . 2 . Histologically confirm cutaneous melanoma either Stage IIIC ( unresectable ) Stage IV ( metastatic ) , determine BRAF V600E/K mutationpositive . 3 . Subjects must fail least two prior systemic anticancer treatment Stage IIIC ( unresectable ) Stage IV ( metastatic ) melanoma must include : Treatment BRAF inhibitor ( include limit dabrafenib , vemurafenib , LGX818 ) progression disease per RECIST , version 1.1 [ Eisenhauer , 2009 ] must document treatment . Treatment ipilimumab ( alternative experimental immunotherapy ) progression disease per immune relate response criterion [ Wolchock Clin Cancer Res December 1 , 2009 15 ; 7412 ] must document treatment . 4 . Documented progression disease per RECIST , version 1.1 [ Eisenhauer , 2009 ] ) per immune relate response criterion [ Wolchock Clin Cancer Res December 1 , 2009 15 ; 7412 ] late systemic therapy administer ipilimumab , antiPD1 antiPDL1 therapy , experimental immunotherapy . 5 . The presence least one measurable lesion per RECIST , version 1.1 [ Eisenhauer , 2009 ] ) . 6 . Interval date last administration prior therapy melanoma date recruitment : &gt; 12 week follow date last administration BRAFinhibitor ; &gt; 12 week follow date first administration &gt; 4 week follow date last administration ipilimumab , antiPD1 , antiPDL1 therapy ; &gt; 4 week follow date last administration chemotherapy ( &gt; 6 week case nitrosurea mitomycin C contain regimen ) ; &gt; 4 week follow major surgery extensive radiotherapy . 7 . Subjects ocular melanoma eligible . 8 . All prior anticancer treatmentrelated toxicity ( except alopecia laboratory value list Table 2 ) must ≤ Grade 1 accord Common Terminology Criteria Adverse Events version 4 ( CTCAE version 4.0 ; National Cancer Institute ( NCI , ) 2009 ) time recruitment . 9 . Able swallow retain oral medication must clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . 10 . Women childbearing potential must negative serum pregnancy test within 7 day prior recruitment agree use effective contraception , define Section 7.3.3.1 , throughout treatment period , 4 month last dose study treatment . 11 . An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 [ Oken , 1982 ] . Refer Appendix 1 detail . 12 . Adequate baseline organ function define Table 2 . 1 . Grade 4 repetitive grade 3 adverse event ( ) relate prior treatment BRAF and/or MEK inhibitor . 2 . Any contraindication evaluation whole body CT MRI brain . 3 . Taken investigational drug within 28 day 5 halflives ( minimum 14 day ) , whichever short , prior recruitment . 4 . Current use prohibit medication describe Section 6 require medication treatment . 5 . History another malignancy , include malignancy confirm activate RAS mutation . Note : Prospective RAS testing require . However , result previous RAS test know , must use assess eligibility . Exception : Subjects diseasefree 3 year , ( i.e . subject second malignancy indolent definitively treat least 3 year ago ) include malignancy confirm activate RAS mutation , subject history completely resect nonmelanoma skin cancer . 6 . Any serious unstable preexist medical condition ( aside malignancy exception specify ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent , compliance study procedure . 7 . Known Human Immunodeficiency Virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV HCV infection permit ) . 8 . Patients progressive symptom active brain metastasis need increase corticosteroid dose control symptom within 4 week prior recruitment exclude 9 . No enzyme inducing anticonvulsant ≥ 4 week prior recruitment 10 . A history evidence cardiovascular risk include follow : Current LVEF &lt; LLN A QT interval correct heart rate use Bazett 's formula ( QTcB ; Section 5.6.3.3 ) ≥480 msec ; A history evidence current clinically significant uncontrolled arrhythmia ; Exception : Subjects atrial fibrillation control &gt; 30 day prior recruitment eligible . A history ( within 6 month prior recruitment ) acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty stenting ; A history evidence current ≥Class II congestive heart failure define New York Heart Association ( NYHA ) guideline ( Appendix 4 ) ; Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mm Hg control antihypertensive therapy ; Patients intracardiac defibrillator ; Abnormal cardiac valve morphology ( ≥grade 2 ) document echocardiogram ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Subjects moderate valvular thickening enter study . 11 . Uncorrectable electrolyte abnormality ( e.g . hypokalaemia , hypomagnesaemia , hypocalcaemia ) , long QT syndrome take medicinal product know prolong QT interval . 12 . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study treatment , excipients , and/or dimethyl sulfoxide ( DMSO ) . 13 . Females pregnant nursing . 14 . Interstitial lung disease pneumonitis 15 . Patients prior history central serous retinopathy retinal vein occlusion exclude . Patients preexist major ocular pathology eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>BRAF V600</keyword>
	<keyword>Rechallenge</keyword>
	<keyword>Combination</keyword>
	<keyword>Dabrafenib</keyword>
	<keyword>Trametinib</keyword>
</DOC>